IP Library Granted Patent US 10,117,880
Granted Patent B2
US 10,117,880 · App. 15/963,878 · Granted Nov 6, 2018

Neridronic acid for treating complex regional pain syndrome

Inventor: Herriot Tabuteau (New York, NY)
Assignee: ANTECIP BIOVENTURES II LLC
A61K31/663A61K9/0019A61K9/0053A61K9/0056A61K9/2004A61K31/573A61K31/675A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,117,880
App. No.
15/963,878
Granted
Nov 6, 2018
Kind
B2
Abstract

Oral dosage forms of osteoclast inhibitors, such as neridronic acid, in an acid form or a salt form can be used to treat or alleviate pain or related conditions, such as allodynia associated with complex regional pain syndrome.

Claims (16)

1. A method of treating severe pain associated with complex regional pain syndrome, comprising administering a parenteral dose of 5 mg to 500 mg of neridronic acid, in a salt form or an acid form, to a human being suffering from severe pain associated with complex regional pain syndrome, wherein the human being has a pain score of at least about 7 on the 0-10 numeric rating scale.

2. The method of claim 1 , wherein the parenteral dose is administered in divided doses of about 10 mg to about 150 mg of the neridronic acid.

3. The method of claim 1 , wherein the human being is suffering from complex regional pain syndrome type I.

4. The method of claim 1 , wherein the human being is suffering from complex regional pain syndrome type II.

5. A method of treating hyperalgesia associated with complex regional pain syndrome, comprising administering a parenteral dose of 5 mg to 500 mg of neridronic acid, in a salt form or an acid form, to a human being suffering from hyperalgesia associated with complex regional pain syndrome.

6. The method of claim 5 , wherein the parenteral dose is administered in divided doses of about 10 mg to about 150 mg of the neridronic acid.

7. The method of claim 5 , wherein the human being is suffering from complex regional pain syndrome type I.

8. The method of claim 5 , wherein the human being is suffering from complex regional pain syndrome type II.

9. A method of treating allodynia associated with complex regional pain syndrome, comprising administering a parenteral dose of 5 mg to 500 mg of neridronic acid, in a salt form or an acid form, to a human being suffering from allodynia associated with complex regional pain syndrome.

10. The method of claim 9 , wherein the parenteral dose is administered in divided doses of about 10 mg to about 150 mg of the neridronic acid.

11. The method of claim 9 , wherein the human being is suffering from complex regional pain syndrome type I.

12. The method of claim 9 , wherein the human being is suffering from complex regional pain syndrome type II.

13. A method of treating edema associated with complex regional pain syndrome, comprising administering a parenteral dose of 5 mg to 500 mg of neridronic acid, in a salt form or an acid form, to a human being suffering from edema associated with complex regional pain syndrome.

14. The method of claim 13 , wherein the parenteral dose is administered in divided doses of about 10 mg to about 150 mg of the neridronic acid.

15. The method of claim 13 , wherein the human being is suffering from complex regional pain syndrome type I.

16. The method of claim 13 , wherein the human being is suffering from complex regional pain syndrome type II.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 23, 2018
From: TABUTEAU, HERRIOT
To: ANTECIP BIOVENTURES II LLC
Reel/Frame 045887/0008 →
Continuity (30)
Continuation 15820305 · Nov 21, 2017
Continuation 15703891 · Sep 13, 2017
Continuation 15360886 · Nov 23, 2016
Continuation In Part 15217773 · Jul 22, 2016
Continuation 14967224 · Dec 11, 2015
Continuation 14604524 · Jan 23, 2015
Continuation In Part 14536526 · Nov 7, 2014
Continuation In Part 14446184 · Jul 29, 2014
Division 14288716 · May 28, 2014
Continuation In Part 14279229 · May 15, 2014
Continuation 14063979 · Oct 25, 2013
Continuation In Part 13894274 · May 14, 2013
Continuation In Part PCTUS2015032739 · May 27, 2015
Continuation PCTUS2014050427 · Aug 8, 2014
Continuation 14279241 · May 15, 2014
Continuation In Part 15647140 · Jul 11, 2017
Provisional Application 61933608 · Jan 30, 2014
Provisional Application 61803721 · Mar 20, 2013
Provisional Application 61767647 · Feb 21, 2013
Provisional Application 61767676 · Feb 21, 2013
Provisional Application 61764563 · Feb 14, 2013
Provisional Application 61762225 · Feb 7, 2013
Provisional Application 61655541 · Jun 5, 2012
Provisional Application 61655527 · Jun 5, 2012
Provisional Application 61654383 · Jun 1, 2012
Provisional Application 61654292 · Jun 1, 2012
Provisional Application 61647478 · May 15, 2012
Provisional Application 61646538 · May 14, 2012
Provisional Application 62378140 · Aug 22, 2016
Related Publication 20180243322A1 · Aug 30, 2018
Cited By (1)
US 12,653,834